foxo4-dri senolytic peptide human trial 2024 2025 Frontiers Senolytic Interventions for Type 2
Senolytic Interventions for Type 2 Diabetes: Current Evidence and Future Directions CHK2 USP37 axis stabilizes FOXO4 to sustain senescence and evade apoptosis PNAS Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging Senotherapy for chronic lung disease ScienceDirect
Pay in 4 interest-free payments of $6.49 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12



